DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Firms / A••••••• C••••••• L•
A••••••• C••••••• L•
A••••••• is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public health challenges.
venture manager, reported GAV $264M across 2 vehicles
Importance
33
moderate
Active deployment
30
moderate
Emerging
0
low
Completeness
69
high
Freshness
99
high
Research priority
13
low
Identity and regulatory footprint
- Headquarters
- New York, NYadviserinfo.sec.gov
- Office address
- 500 5TH AVENUE, SUITE 4000, New York, NY, 10110adviserinfo.sec.gov
- Business phone
- 9173340724adviserinfo.sec.gov
- Website
- a•••••••••.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 27, 2026
- Private funds reported
- 2 (2 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $170Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- A••••••• C•••••• M••••••••• L•• (General Partner), NA
- business email
- yanatos@adjuvantcapital.comadjuvantcapital.compublished by the subject
- business phone
- 9173340724adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
16 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, biotech, climate
- Stages
- not stated or not yet read
- Geography
- global, middle east
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 94%Biotechnology 6%
lead rate n/afollow-on rate n/anew logos, 12 months 16
Funds and vehicles
2 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| A••••••• G••••• H••••• T••••••••• F•••• L••• | Fund | 2019 form d first sale | Mature | $222M Mar 28, 2024 | 21 | $252M of $252M | Feb 23, 2021 |
| A••••••• G••••• H••••• T••••••••• F••• D•• L••• | Fund | 2019 form d first sale | Mature | $41.6M Mar 28, 2024 | 14 | $48.2M of $48.2M | Feb 23, 2021 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
22 current, 1 departed
A•••• H••••
AssociateAssociate
G••••• B••••••
AssociateAssociate
C•••••••• M••••
Board or advisorySenior Advisor
J•• R•••••••
Board or advisorySenior Advisor
M••••• G••••••
Board or advisorySenior Advisor
M•••••• H•••••
Board or advisorySenior Advisor
N••• A••••••
Board or advisorySenior Advisor
P•••• P••••••••
Board or advisorySenior Advisor
S••••• A•••••••
Board or advisorySenior Advisor
G•••• R••••••
General partnerCo-Founder and Partner
K••••• A•••
General partnerCo-Founder and Partner
G••••• C•••••••••
Operating partnerOperating Partner
K••• A•••••••
Operating partnerOperating Partner
S••• N•••••••••
OtherPortfolio
A•••••••• ••••••• G•••••••••
PartnerAdvisory Partner
G•••• A•••••• R••••••
PartnerSole Member · since May 1, 2019
K••••• A•••
PartnerPartner · since Aug 1, 2022
P••••••• D••
PartnerPartner
E••••• B••• Y••••••
Platform and operationsDirector Of Finance And Compliance; Chief Compliance Officer · since May 1, 2019
E••••• Y••••••
Platform and operationsDirector of Finance and Compliance
M••• S•••••••
Venture partnerVenture Partner
N•• Y•••
Venture partnerVenture Partner
1 departed (kept with end dates)
- J•••• C••••••••• Y•• · Managing Partner · May 1, 2019 to Sep 15, 2022 Inference
Investments on record
16 edges, 16 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
6 relationships from shared deals, counted for the whole firm
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
19 dated events
- Sep 16, 2026I••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceI•••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026T•••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceT••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026A••••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceA•••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 20265••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInference5•••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026C••••••••• I••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceC••••••••• I•••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Q••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceQ•••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026E••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceE•••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026V••••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceV•••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026F••••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceF•••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026P•••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceP••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026A•••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceA••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026C••••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceC•••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026M••••••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceM•••••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026L••••• no longer listed on A••••••• C••••••• L•'s portfolio pageRemoved from portfolio pagePortfolioInferenceL•••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Sep 15, 2022J•••• C••••••••• Y•• (Managing Partner) no longer on Schedule A of A••••••• C••••••• L•
- Aug 1, 2022K••••• A••• joined Schedule A of A••••••• C••••••• L• as Partner
- Mar 10, 2020A••••••• G••••• H••••• T••••••••• F••• D•• L••• first reported on Form ADV by A••••••• C••••••• L• (Private Equity Fund), GAV $33,500,000Fund first reported on Form ADVFundsFactA••••••• G••••• H••••• T••••••••• F••• D•• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 13, 2019A••••••• G••••• H••••• T••••••••• F•••• L••• first reported on Form ADV by A••••••• C••••••• L• (Private Equity Fund)Fund first reported on Form ADVFundsFactA••••••• G••••• H••••• T••••••••• F•••• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 13, 2019A••••••• C••••••• L• first filed Form ADV (ERA)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $264M across 2 vehicles
Evidence
51 observations from 3 sources